Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections

Pharmacotherapy

Volumn 35, Issue 2, 2015, Pages 127-139

  Adane, Eyob D ^a   Herald, Michael ^a   Koura, Firas ^b  

^a OHIO NORTHERN UNIVERSITY   (United States)

^b Kentucky Lung Clinic PSC Appalachian Regional Healthcare   (United States)

Author keywords

NONMEM; obesity; peak; pharmacokinetics; trough; vancomycin

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CEFEPIME; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; MEROPENEM; NONSTEROID ANTIINFLAMMATORY AGENT; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CLINICAL ARTICLE; CREATININE CLEARANCE; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; MINIMUM PLASMA CONCENTRATION; MORBID OBESITY; NONHUMAN; PHARMACOKINETIC ASSAY; PLASMA CONCENTRATION-TIME CURVE; PROSPECTIVE STUDY; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STEADY STATE; URINALYSIS; BIOLOGICAL MODEL; BODY WEIGHT; INTRAVENOUS DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; PHYSIOLOGY; STAPHYLOCOCCAL INFECTIONS; TEACHING HOSPITAL; TISSUE DISTRIBUTION;

ADULT; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HOSPITALS, TEACHING; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MODELS, BIOLOGICAL; OBESITY, MORBID; PROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TISSUE DISTRIBUTION; VANCOMYCIN;

EID: 84923479118     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1531     Document Type: Article

References (47)

1. Moellering RC,. Vancomycin: a 50-year reassessment. Clin Infect Dis 2006; 42 (Suppl 1): S3-4.
2. Rodvold KA, Blum RA, Fischer JH, et al. Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother 1988; 6: 848-52.
3. Rotschafer JC, Crossley K, Zaske DE, Mead K, Sawchuk RJ, Solem LD,. Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations. Antimicrob Agents Chemother 1982; 3: 391-4.
4. Ducharme MP, Slaughter RL, Edwards DJ,. Vancomycin pharmacokinetics in a patient population: effect of age, gender, and body weight. Ther Drug Monit 1994; 5: 513-8.
5. Blouin RA, Bauer LA, Miller DD, Record KE, Griffen WO Jr,. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother 1982; 4: 575-80.
6. Golper TA, Noonan HM, Elzinga L, et al. Vancomycin pharmacokinetics, renal handling, and nonrenal clearances in normal human subjects. Clin Pharmacol Ther 1988; 5: 565-70.
7. Matzke GR, McGory RW, Halstenson CE, Keane WF,. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother 1984; 4: 433-7.
8. Butterfield JM, Patel N, Pai MP, Rosano TG, Drusano GL, Lodise TP,. Refining vancomycin protein binding estimates: identification of clinical factors that influence protein binding. Antimicrob Agents Chemother 2011; 9: 4277-82.
9. Rybak MJ,. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 2006; 42 (Suppl 1): S35-9.
10. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009; 66: 82-98.
11. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 2011; 3: 285-92.
12. Falagas ME, Kompoti M,. Obesity and infection. Lancet Infect Dis 2006; 7: 438-46.
13. Shipman AR, Millington GW,. Obesity and the skin. Br J Dermatol 2011; 4: 743-50.
14. Centers for Disease Control and Prevention. U.S. Obesity Trends. Available from http://www.cdc.gov/nchs/data/databriefs/db82.htm. Accessed December 18, 2014.
15. World Health Organization. BMI Classification. Available from http://apps.who.int/bmi/index.jsp?introPage=intro-3.html. Accessed November 20, 2013.
16. Moellering RC Jr, Krogstad DJ, Greenblatt DJ,. Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Ann Intern Med 1981; 3: 343-6.
17. Bauer LA,. Applied clinical pharmacokinetics, 2nd ed. New York: McGraw-Hill, 2008.
18. Lodise TP, Lomaestro B, Graves J, Drusano GL,. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008; 4: 1330-6.
19. Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL,. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 2009; 4: 507-14.
20. Rybak MJ, Albrecht LM, Boike SC, Chandrasekar PH,. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother 1990; 4: 679-87.
21. Patel N, Pai MP, Rodvold KA, Lomaestro B, Drusano GL, Lodise TP,. Vancomycin: we can't get there from here. Clin Infect Dis 2011; 8: 969-74.
22. Bosch K, McLaughlin MM, Esterly JS, Rhodes NJ, Postelnick MJ, Scheetz MH,. Impact of vancomycin treatment duration and dose on kidney injury. Int J Antimicrob Agents 2014; 3: 297-8.
23. Bauer LA, Black DJ, Lill JS,. Vancomycin dosing in morbidly obese patients. Eur J Clin Pharmacol 1998; 8: 621-5.
24. Cockcroft DW, Gault MH,. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 1: 31-41.
25. Dubois D, Dubois EF,. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 1916; 17: 863-71.
26. Demirovic JA, Pai AB, Pai MP,. Estimation of creatinine clearance in morbidly obese patients. Am J Health Syst Pharm 2009; 7: 642-8.
27. Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B,. Quantification of lean bodyweight. Clin Pharmacokinet 2005; 10: 1051-65.
28. Salazar DE, Corcoran GB,. Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass. Am J Med 1988; 6: 1053-60.
29. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 4: 247-54.
30. Davis GA, Lewis DA,. Clinical pharmacokinetic service and anticoagulation guidelines. Lexington, KY: Pharmacy Services University of Kentucky Hospital; 2010.
31. Beal S, Sheiner LB, Boeckmann A, Bauer RJ,. NONMEM user's guides (1989-2013). Ellicott City, MD: Icon Development Solutions, 2013.
32. Holford NHG. Wings for NONMEM, v. 731 for NONMEM 7.3. 2013. Available from http://wfn.sourceforge.net.
33. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2013. Available from http://www.R-project.org/.
34. Craig WA,. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am 2003; 3: 479-501.
35. Moise PA, Forrest A, Bhavnani SM, Birmingham MC, Schentag JJ,. Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus. Am J Health Syst Pharm 2000; 57 (Supplement 2): S4-9.
36. Brown J, Brown K, Forrest A,. Vancomycin AUC24/MIC ratio in patients with complicated bacteremia and infective endocarditis due to methicillin-resistant Staphylococcus aureus and its association with attributable mortality during hospitalization. Antimicrob Agents Chemother 2012; 2: 634-8.
37. Steinkraus G, White R, Friedrich L,. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J Antimicrob Chemother 2007; 4: 788-94.
38. Lodise TP, Graves J, Evans A, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008; 9: 3315-20.
39. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A,. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006; 19: 2138-44.
40. van Hal SJ, Paterson DL, Lodise TP,. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother 2013; 2: 734-44.
41. Burton ME, Gentle DL, Vasko MR,. Evaluation of a Bayesian method for predicting vancomycin dosing. DICP 1989; 4: 294-300.
42. Murphy JE, Gillespie DE, Bateman CV,. Predictability of vancomycin trough concentrations using seven approaches for estimating pharmacokinetic parameters. Am J Health Syst Pharm 2006; 23: 2365-70.
43. Marsot A, Boulamery A, Bruguerolle B, Simon N,. Vancomycin: a review of population pharmacokinetic analyses. Clin Pharmacokinet 2012; 1: 1-13.
44. Reynolds DC, Waite LH, Alexander DP, DeRyke CA,. Performance of a vancomycin dosage regimen developed for obese patients. Am J Health Syst Pharm 2012; 11: 944-50.
45. Brown DL, Lalla CD, Masselink AJ,. AUC versus peak-trough dosing of vancomycin: applying new pharmacokinetic paradigms to an old drug. Ther Drug Monit 2013; 4: 443-9.
46. Sakoulas G, Gold HS, Cohen RA, Venkataraman L, Moellering RC, Eliopoulos GM,. Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia. J Antimicrob Chemother 2006; 4: 699-704.
47. Cruciani M, Gatti G, Lazzarini L, et al. Penetration of vancomycin into human lung tissue. J Antimicrob Chemother 1996; 5: 865-9.